Extended Data Fig. 4: Antecedent Dose, Platelet Count, Prothrombin International Normalized Ratio (INR), Activated Partial Thromboplastin Time (aPTT) and Platelet Transfusions in Patients Who had Intracranial Bleeding Events (AdvSM Safety Population).
From: Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
*Nadir platelet count presented as value during screening/nadir value within 56 days prior to event onset. †Baseline INR and aPTT presented as values during screening/maximum values within 56 days prior to event onset. ‡Total number of units of platelets given by transfusion, after first dose of avapritinib and prior to the onset of a first intracranial bleeding event. AdvSM, advanced systemic mastocytosis; aPTT, activated partial thromboplastin time; ASM, aggressive systemic mastocytosis; CTCAE, Common Terminology Criteria for Adverse Events; INR, prothrombin international normalized ratio; MCL, mast cell leukemia; NR, not recorded; RAC, Response Adjudication Committee; SM-AHN, systemic mastocytosis with an associated hematologic neoplasm.
